Century Therapeutics, Inc. Cash Flow Statement
IPSC|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$110M
FY2025
Free Cash Flow
-$110M
FY2025
Capital Expenditures
$154,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Century Therapeutics, Inc. used $110M in operating cash flow and negative free cash flow of $110M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$126.6M | -$136.7M | -$130.9M | -$95.8M |
| Depreciation & Amortization | $13.3M | $13.0M | $8.4M | $3.7M |
| Operating Cash Flow | -$110.1M | -$88.3M | $14.1M | -$89.0M |
| Capital Expenditures | $154.0K | $13.7M | $30.6M | $45.0M |
| Free Cash Flow | -$110.3M | -$102.1M | -$16.6M | -$134.0M |
| FCF Margin | -1673.8% | -4567.5% | -318.4% | -2576.9% |